Evidence map›Paper›PMID 39405332›Full record

ArticlePLoS pathogens2024

Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection.

Michael Schoefbaenker, Theresa Günther, Eva Ulla Lorentzen, Marie-Luise Romberg, Marc Tim Hennies, Rieke Neddermeyer, Marlin Maybrit Müller, Alexander Mellmann, Chiara Robin Bojarzyn, Georg Lenz and 6 more

Abstract readCase Reports
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Michael SchoefbaenkerInstitute of Virology Muenster, University of Muenster, Muenster, Germany.
Theresa GüntherInstitute of Virology Muenster, University of Muenster, Muenster, Germany.
Eva Ulla LorentzenInstitute of Virology Muenster, University of Muenster, Muenster, Germany.
Marie-Luise RombergInstitute of Virology Muenster, University of Muenster, Muenster, Germany.
Marc Tim HenniesInstitute of Virology Muenster, University of Muenster, Muenster, Germany.
Rieke NeddermeyerInstitute of Virology Muenster, University of Muenster, Muenster, Germany.
Marlin Maybrit MüllerInstitute of Virology Muenster, University of Muenster, Muenster, Germany.
Alexander MellmannInstitute of Hygiene, University Hospital Muenster, University of Muenster, Muenster, Germany.
Chiara Robin BojarzynInstitute of Virology Muenster, University of Muenster, Muenster, Germany.
Georg LenzDepartment of Medicine A, Haematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
Matthias StelljesDepartment of Medicine A, Haematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
Eike Roman HrinciusInstitute of Virology Muenster, University of Muenster, Muenster, Germany.
Richard VollenbergDepartment of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, Muenster, Germany.
Stephan LudwigInstitute of Virology Muenster, University of Muenster, Muenster, Germany.
Phil-Robin TepasseDepartment of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, Muenster, Germany.
Joachim Ewald KühnInstitute of Virology Muenster, University of Muenster, Muenster, Germany.

Funding

Ministry of Culture and Science, NRW, GermanyThe Institute of Virology
6 · The paper itself

Abstract

Neutralising antibodies against the SARS-CoV-2 spike (S) protein are major determinants of protective immunity, though insufficient antibody responses may cause the emergence of escape mutants. We studied the humoral immune response causing intra-host evolution in a B-cell depleted, haemato-oncologic patient experiencing clinically severe, prolonged SARS-CoV-2 infection with a virus of lineage B.1.177.81. Following bamlanivimab treatment at an early stage of infection, the patient developed a bamlanivimab-resistant mutation, S:S494P. After five weeks of apparent genetic stability, the emergence of additional substitutions and deletions within the N-terminal domain (NTD) and the receptor binding domain (RBD) of S was observed. Notably, the composition and frequency of escape mutations changed in a short period with an unprecedented dynamic. The triple mutant S:Delta141-4 E484K S494P became dominant until virus elimination. Routine serology revealed no evidence of an antibody response in the patient. A detailed analysis of the variant-specific immune response by pseudotyped virus neutralisation test, surrogate virus neutralisation test, and immunoglobulin-capture enzyme immunoassay showed that the onset of an IgM-dominated antibody response coincided with the appearance of escape mutations. The formation of neutralising antibodies against S:Delta141-4 E484K S494P correlated with virus elimination. One year later, the patient experienced clinically mild re-infection with Omicron BA.1.18, which was treated with sotrovimab and resulted in an increase in Omicron-reactive antibodies. In conclusion, the onset of an IgM-dominated endogenous immune response in an immunocompromised patient coincided with the appearance of additional mutations in the NTD and RBD of S in a bamlanivimab-resistant virus. Although virus elimination was ultimately achieved, this humoral immune response escaped detection by routine diagnosis and created a situation temporarily favouring the rapid emergence of various antibody escape mutants with known epidemiological relevance.

Indexed as

Antibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralCOVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19 Drug TreatmentHumansImmunity, HumoralMaleMiddle AgedMutationAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralbamlanivimabSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID39405332
PMCPMC11508484

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.